ATE299496T1 - Pyridiniumverbindungen zur behandlung von age- relatierten krankheiten - Google Patents

Pyridiniumverbindungen zur behandlung von age- relatierten krankheiten

Info

Publication number
ATE299496T1
ATE299496T1 AT01201057T AT01201057T ATE299496T1 AT E299496 T1 ATE299496 T1 AT E299496T1 AT 01201057 T AT01201057 T AT 01201057T AT 01201057 T AT01201057 T AT 01201057T AT E299496 T1 ATE299496 T1 AT E299496T1
Authority
AT
Austria
Prior art keywords
compounds
treatment
age
discloses
related diseases
Prior art date
Application number
AT01201057T
Other languages
English (en)
Inventor
Alangudi Sankaranarayanan
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE299496T1 publication Critical patent/ATE299496T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AT01201057T 2001-03-21 2001-03-21 Pyridiniumverbindungen zur behandlung von age- relatierten krankheiten ATE299496T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01201057A EP1243581B1 (de) 2001-03-21 2001-03-21 Pyridiniumverbindungen zur Behandlung von AGE-relatierten Krankheiten
JP2001081819A JP4471141B2 (ja) 2001-03-21 2001-03-22 老化関連及び糖尿病脈管合併症の管理のための新規化合物、その製造方法及び治療的使用
CA002341949A CA2341949C (en) 2001-03-21 2001-03-23 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses
CNB01112413XA CN1148351C (zh) 2001-03-21 2001-03-30 用于治疗脉管并发症的化合物,其制备方法及治疗应用

Publications (1)

Publication Number Publication Date
ATE299496T1 true ATE299496T1 (de) 2005-07-15

Family

ID=27427687

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01201057T ATE299496T1 (de) 2001-03-21 2001-03-21 Pyridiniumverbindungen zur behandlung von age- relatierten krankheiten

Country Status (10)

Country Link
EP (1) EP1243581B1 (de)
JP (1) JP4471141B2 (de)
CN (1) CN1148351C (de)
AT (1) ATE299496T1 (de)
CA (1) CA2341949C (de)
DE (1) DE60111919T2 (de)
DK (1) DK1243581T3 (de)
ES (1) ES2243389T3 (de)
HK (1) HK1045996B (de)
PT (1) PT1243581E (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110034378A1 (en) * 2008-01-25 2011-02-10 Chaitanya Dutt Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc.
WO2010055170A1 (en) * 2008-11-17 2010-05-20 Technische Universität München Pyrimidinium derivatives for use in the treatment or prevention of diabetes
EP2427432A2 (de) * 2009-05-07 2012-03-14 Torrent Pharmaceuticals Limited Neue heterozyklische verbindungen
CA2997463A1 (en) 2015-04-08 2016-10-13 Torrent Pharmaceuticals Limited Pharmaceutical formulations
AR104274A1 (es) 2015-04-08 2017-07-12 Torrent Pharmaceuticals Ltd Compuestos piridinio como inhibidores de pag
CN119768393A (zh) 2022-05-25 2025-04-04 医肯纳肿瘤学公司 Mek抑制剂和其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH335521A (de) * 1955-06-02 1959-01-15 Cilag Ag Verfahren zur Herstellung neuer quaternärer Salze
JPH0232006A (ja) * 1988-07-21 1990-02-01 Shiseido Co Ltd 皮膚外用剤
JP2817219B2 (ja) * 1988-09-08 1998-10-30 武田薬品工業株式会社 カルバジン酸誘導体、その製造法及び製剤
JPH08175995A (ja) * 1994-12-21 1996-07-09 Green Cross Corp:The 糖化蛋白変成物質生成阻害剤
EP0808163B1 (de) * 1995-01-18 2003-07-23 Alteon, Inc. Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
ES2183171T3 (es) * 1996-05-08 2003-03-16 Alteon Inc Sales de imidazolio sustituido y su uso para la inhibicion del envejecimiento de proteinas.
JP2001519813A (ja) * 1997-04-04 2001-10-23 スミスクライン・ビーチャム・コーポレイション カルシウム溶解性化合物
JPH11106352A (ja) * 1997-08-08 1999-04-20 Chugai Pharmaceut Co Ltd 糖尿病合併症治療剤
JPH11292881A (ja) * 1998-04-02 1999-10-26 Shionogi & Co Ltd １Ｈ−ピロロ［３，２−ｃ］ピリジニウム誘導体
MXPA02003496A (es) * 1999-10-06 2005-06-20 Torrent Pharmaceuticals Ltd Derivados de piridinio para el tratamiento de complicaciones vasculares diabeticas y relacionadas con la edad.
ES2216644T3 (es) * 1999-10-06 2004-10-16 Torrent Pharmaceuticals Ltd Derivados de piridinio utiles para el tratamiento de complicaciones vasculares relacionadas con el envejecimiento y procedimiento de preparacion y uso de los mismos.
CZ20014034A3 (cs) * 2001-10-19 2003-06-18 Torrent Pharmaceuticals Ltd. Kosmetický prostředek, způsob a prostředek a vychytávání volných radikálů z těla buněk

Also Published As

Publication number Publication date
CA2341949C (en) 2005-10-11
HK1045996B (en) 2006-02-03
DE60111919T2 (de) 2006-04-20
JP2002275158A (ja) 2002-09-25
DE60111919D1 (de) 2005-08-18
HK1045996A1 (en) 2002-12-20
PT1243581E (pt) 2005-11-30
CN1148351C (zh) 2004-05-05
ES2243389T3 (es) 2005-12-01
DK1243581T3 (da) 2005-10-31
CA2341949A1 (en) 2002-09-23
EP1243581B1 (de) 2005-07-13
EP1243581A1 (de) 2002-09-25
JP4471141B2 (ja) 2010-06-02
CN1377880A (zh) 2002-11-06

Similar Documents

Publication Publication Date Title
ATE508738T1 (de) System zur beabstandeten abgabe von arzneimitteln
Esper et al. The effect of two phototherapy protocols on pain control in orthodontic procedure—a preliminary clinical study
MXPA02003495A (es) Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos.
BR9906813A (pt) Método para administração de insulina aspb28- humana
EP1064000A4 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
JP2006501240A5 (de)
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
AR047779A1 (es) Composiciones y metodos para tratar diabetes
CA2503810A1 (en) Therapeutic agent for fibromyalgia
AR032065A1 (es) Derivados de glucopiranosiloxipirazol y composicion farmaceutica
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
WO2003051388A3 (en) Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
DE69634556D1 (de) L-Carnitin oder ihre Derivate und Resveratrol oder ihre Derivate zur Vorbeugung und Behandlung von kardiovaskulären Erkrankungen, peripheren Gefässkrankheit, peripheren diabetischen Neuropathie und diese enthaltende pharmazeutische Zusammensetzungen
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
Loughran et al. Unilateral retrobulbar hematoma following maxillary nerve block in a dog
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
DE60111919D1 (de) Pyridiniumverbindungen zur Behandlung von AGE-relatierten Krankheiten
HK1044336A1 (zh) 治疗糖尿病及衰老相关性血管性并发症的吡啶衍生物
EP1393738A4 (de) Arzneimittel gegen diabetes
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
RU96115219A (ru) Способ лечения больных сахарным диабетом
Mulkey Outpatient treatment of hemophiliacs for dental extractions
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
BR0104586A (pt) Método para tratamento de neurodegeneração

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1243581

Country of ref document: EP